(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of -5.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Vir Biotechnology's revenue in 2024 is $86,180,000.On average, 4 Wall Street analysts forecast VIR's revenue for 2024 to be $7,464,178,678, with the lowest VIR revenue forecast at $3,375,806,700, and the highest VIR revenue forecast at $16,446,930,242. On average, 4 Wall Street analysts forecast VIR's revenue for 2025 to be $7,073,260,262, with the lowest VIR revenue forecast at $3,551,348,648, and the highest VIR revenue forecast at $14,340,426,862.
In 2026, VIR is forecast to generate $10,418,819,734 in revenue, with the lowest revenue forecast at $4,364,242,902 and the highest revenue forecast at $18,634,452,984.